A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

AI-assisted imaging improved prostate cancer diagnosis and biopsy decision-making in new research presented at EAU 2026.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix (kit for the preparation of gallium-68 (68Ga) gozetotide ...

LOS ANGELES & RESTON, Va.--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced a collaboration that will provide funding and ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...